Jason Foster, CEO of Ori Biotech, discusses the difficulties preventing more widespread adoption of these advanced therapies.

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04-13 study in patients with Alcohol Use Disorder ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

A new offering in collaboration with Progyny, Inc makes fertility/family-building services more accessible and equitable.

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

Amylyx Pharmaceuticals named Dan Monahan as its chief commercial officer. 1 According to a press release, he is assuming the role in time to oversee the commercialization of avexitide, a GLP-1 ...

San Francisco Police cancel time off requests to increase security at the J.P. Morgan Healthcare Conference after the recent murder of UnitedHealth Group CEO Brian Thompson. In the wake of the murder ...

Blue Shield of California issued a statement regarding the devastating wildfires that have spread across large sections of the state. 1 While the combination of flames and winds continue to cause ...

‘Shape Shifting’ is a creator-led series that focuses on the scientific and cultural impact of GLP-1s. The two biggest stories in pharma in recent years have been the rise in popularity of GLP-1s and ...

Priority Review was based on results from the Phase III Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia gravis. The FDA has granted Priority Review to a Biologics License ...